Stock XSPRAY XSPRAY PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:35 2024-06-07 am EDT 		5-day change 1st Jan Change
71.8 SEK -1.64% Intraday chart for Xspray Pharma AB -3.23% +79.50%
May. 23 Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib CI
May. 20 Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
New number of shares and votes in Xspray Pharma after TO6
AQ
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
BU
Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib
CI
Bulletin from the annual general meeting of Xspray Pharma AB (publ), 21 May 2024
AQ
Xspray Pharma appoints Chief Operating Officer and changes the Management Team
AQ
Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024
CI
Xspray Pharma AB Appoints Niklas Adenborg as Chief Financial Officer, Effective July 1, 2024
CI
Xspray Pharma Q1 2024 - Reveal of XS025 and PDUFA is nearing
AQ
Interim Report First Quarter 2024
AQ
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Xspray Pharma raises SEK 100.3 million through warrants TO6
AQ
Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market
AQ
Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market
CI
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants
AQ
Important information to holders of warrants series TO6: subscription period begins today
AQ
Notice of annual general meeting of Xspray Pharma AB (publ)
AQ
Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants
AQ
Xspray Pharma publishes its Annual Report 2023
AQ
Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA
AQ
Interim Report Fourth Quarter 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XSPRAY Stock
  4. News Xspray Pharma AB